Skip to main content

Closed

GRCE: Grace Therapeutics, Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth+0.0% / yr

Operating margin0.0%

ROIC-16.9%

Financially safe

Stretched

Debt / equity0.00×

Interest coverage0.0×

Current ratio8.10×

Grace Therapeutics, Inc.

GRCENASDAQ Global Market·USD·Closed

Grace Therapeutics, Inc.

GRCENASDAQ·USD·Closed

$2.08

+0.48%

$2.08

+$0.01 (0.48%)

52W Range

9thpctl

Volume

0.58×avg

Mkt Cap

33.85MUSD

P/E

-3.7TTM

Div Yield

–ann

52W Range

9thpctl

Volume

0.58×avg

Market Cap

33.85MUSD

P/E Ratio

-3.7TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings